Vitamin D Supplementation in HIV Youth

Vitamin D Supplementation and HIV-related Complications in Children and Young Adults

The purpose of this study is to determine the correct dose of Vitamin D to give to prevent HIV related complications.

The purpose of the this study was to compare control dose of vitamin D (low dose of 600 IU/d) to supplementation dose (medium dose of 2000 IU/d or higher doses of vitamin D of 4000 IU/d) on HIV-related comorbidities including immune activation, inflammation, cardiovascular diseases, and metabolic complications in HIV-infected youth.

Inclusion Criteria:

• Ages 8-25
• Documented HIV-1 infection
• On stable antiretroviral therapy for > 3 months
• Cumulative antiretroviral therapy of at least 6 months
• 25(OH)D level < 30 ng/ml at screening

Exclusion Criteria:

• > 400 IU daily regular vitamin D intake
• Parathyroid/calcium disorders
• Active malignancy
• Pregnancy/intent to become pregnant/breastfeeding
• Chronic infectious/inflammatory conditions
• Creatinine clearance < 50 ml/min
• Hemoglobin < 9.0 g/dL
• Aspartate aminotransferase and alanine aminotransferase > 2.5 upper limit of normal
• Diabetes requiring hypoglycemic agents
• Known coronary artery disease
• Inability to swallow pills